All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Darazam, 2021 1.21 [0.65; 2.25]
Li, 2021 1.04 [0.02; 53.73]
Wang, 2020 1.00 [0.02; 52.54]
1.20 [0.65 ; 2.20 ] Darazam, 2021, Li, 2021, Wang, 2020 3 0% 310 moderate not evaluable clinical deteriorationdetailed results Li, 2021 0.52 [0.02; 15.78]
Wang, 2020 1.00 [0.02; 52.54]
0.68 [0.05 ; 9.11 ] Li, 2021, Wang, 2020 2 0% 142 moderate not evaluable clinical improvementdetailed results Darazam, 2021 1.37 [0.88; 2.13]
Li, 2021 1.76 [1.10; 2.81]
1.54 [1.12 ; 2.12 ] Darazam, 2021, Li, 2021 2 0% 264 moderate not evaluable clinical improvement (14-day)detailed results Li, 2021 2.86 [1.24; 6.62]
2.86 [1.24 ; 6.62 ] Li, 2021 1 0% 94 NA not evaluable clinical improvement (28-day)detailed results Li, 2021 4.26 [1.10; 16.44]
4.26 [1.10 ; 16.44 ] Li, 2021 1 0% 94 NA not evaluable clinical improvement (7-day)detailed results Li, 2021 1.83 [0.41; 8.14]
1.83 [0.41 ; 8.14 ] Li, 2021 1 0% 94 NA not evaluable clinical improvement (time to event analysis only)detailed results Darazam, 2021 1.37 [0.88; 2.13]
Li, 2021 1.76 [1.10; 2.81]
1.54 [1.12 ; 2.12 ] Darazam, 2021, Li, 2021 2 0% 264 moderate not evaluable mechanical ventilationdetailed results Li, 2021 0.52 [0.02; 15.78]
0.52 [0.02 ; 15.78 ] Li, 2021 1 0% 94 NA not evaluable viral clearance detailed results Li, 2021 7.68 [0.91; 65.15]
7.68 [0.91 ; 65.15 ] Li, 2021 1 0% 94 NA not evaluable viral clearance (time to event analysis only)detailed results Li, 2021 1.74 [1.10; 2.75]
1.74 [1.10 ; 2.75 ] Li, 2021 1 0% 96 NA not evaluable viral clearance by day 14detailed results Li, 2021 1.74 [0.71; 4.29]
1.74 [0.71 ; 4.29 ] Li, 2021 1 0% 94 NA not evaluable viral clearance by day 7detailed results Li, 2021 2.20 [0.95; 5.10]
2.20 [0.95 ; 5.10 ] Li, 2021 1 0% 94 NA not evaluable related SAE (TRSAE)detailed results Wang, 2020 2.04 [0.07; 63.93]
2.04 [0.07 ; 63.93 ] Wang, 2020 1 0% 48 NA not evaluable adverse eventsdetailed results Wang, 2020 3.57 [0.93; 13.72]
3.57 [0.93 ; 13.72 ] Wang, 2020 1 0% 48 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-14 08:59 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290
